In a study published in Cell Stem Cell, scientists tested retinal pigment epithelial stem cells in a phase 1/2a clinical trial. The cells were obtained from adult postmortem eye tissue. These ...
The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...
A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...
By reducing inflammation, the researchers were able to prevent both the buildup of immune cells and the formation of these ...
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect ...
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...
ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA ...
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
On track to report topline 56-week data for LUGANO in mid-2026 with LUCIA data to closely follow – WATERTOWN, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a ...
The gene therapy will utilize the firm's suprachoroidal vector coAAV-SCS, which it says will be an effective and less burdensome treatment alternative.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback